Investing.com - Financial Markets Worldwide

Supernus Pharmaceuticals Inc (SUPN)

NASDAQ
Symbol
Exchange
Currency
32.96
-0.18(-0.54%)
-Closed.
Currency in USD
After Hours
33.14
+0.18(+0.55%)
- Real-time Data
  • Volume:
    526,627
  • Day's Range:
    32.58 - 33.32
  • 52 wk Range:
    25.80 - 42.09

SUPN Historical Data

Time Frame:
Daily
Download Data
05/02/2023 - 06/02/2023
32.9633.1333.3232.58526.95K-0.54%
33.1433.3333.8532.90365.67K-0.36%
33.2633.6233.9433.11331.31K-1.07%
33.6233.4333.7633.30179.68K+0.24%
33.5433.4634.5033.16372.92K-0.50%
33.7134.0334.1933.42386.91K-1.03%
34.0634.5434.6533.66505.65K-1.33%
34.5235.2735.5433.97466.91K-2.18%
35.2935.4535.5834.94451.03K+0.92%
34.9735.2735.4434.54395.34K-0.63%
35.1935.2735.4234.32391.66K+0.09%
35.1634.4435.2834.22338.73K+1.21%
34.7434.2635.0034.00395.97K+1.79%
34.1335.8135.9633.22637.64K-4.93%
35.9036.6037.4235.73398.80K-2.23%
36.7237.0038.0835.53849.47K+1.49%
36.1836.6936.7236.18362.10K-1.66%
36.7936.6736.9635.98281.31K+0.22%
36.7136.8037.0836.09259.83K+0.66%
36.4737.0037.0035.81346.21K-2.02%
37.2237.3138.0937.15287.50K-0.16%
37.2836.7337.4236.72300.37K+0.89%
Highest: 38.09Lowest: 32.58Difference: 5.51Average: 35.07Change %: -10.80
  • good fundamentals, discount price, solid company. Nice price to add @ 25,20?
    0
    Show previous replies (2)
    • Josef Kurzmannwhat do you find it was not good in the last report?
      0
    • declining earnings and revenues compared to the prior quarter.
      0
    • i know if the earnings and revenues decline for 1 quarter it isn't a big thing but what will happen if they decline for 2 or 3 quarters, we would possible see $15
      0
  • i sold a couple of days ago, seems like the real market crash is finally coming. I'll re-visit SUPN in a couple of months and decide if the share price fell deep enough.
    3
    • yesterday i sent this stock as an "tip" to some stock advisors and hedge funds (only about 5 combined). the price rose 4.38% and today it is up 3.39% in the pre-market. i will tell more fund managers about this stock and then the price should jump really quick.
      3
      • That moment when Josef thinks he is moving markets 😂
        1
    • one more time:I don't have the knowledge to make an educated guess if the FDA will or will not approve the new ADHD treatment and i am pretty sure you don't have the knowledge and insight eigther.What i know if that SUPN had a great balance sheet, is growing it's revenues 30% per year/earnings 40% per year both since 2016. I also know that their P/E ratio is at 12.5. so i can tell you, even if the new drug doesn't get approved the stock should be at around $90 per share (4.5 billion market cap). Right now it is at $30. If the new drug gets approved it should easily be at $100+ by the end of next year (December 2022) that is a 200%+ return in 23 months.
      1
      • BBRW
        1
    • supernus has a great risk/reward ratio. since 2016 earnings and revenues more than doubled yet the stock price is down 50% ($30 as I'm writing) . revenues and earnings are growing very fast (30%/40%p.a.) and this all makes it very likely that this stock quadrouples over the next 3-5 years.
      1
      • and i didn't even factor in that they have a new revolutionary treatment for ADHD in trial 3 that could be approved by the FDA (then the stock would be worth even more).
        1